Generate Capital Raises over $1 Billion to Expand Infrastructure Credit Solutions
SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ — Generate Capital (“Generate”), a leading sustainable infrastructure investment platform, today announced... Read more.
Callan Publishes Asset Manager Sustainable Investment Practices Study
Findings show how asset managers integrate sustainability factors into their investment processes SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ — Callan, a leading... Read more.
MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome
-First Gene Therapy Trial for Angelman Syndrome -Orphan Drug Designation Granted for MVX-220 MIDDLETON, Mass., Nov. 6, 2025 /PRNewswire/ — MavriX Bio, a clinical-stage... Read more.
Eilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025
DOVER, Del., Nov. 6, 2025 /PRNewswire/ — Eilean Therapeutics LLC, a biotechnology company developing next-generation precision medicines for cancer and immune-inflammatory... Read more.
ATDev Joins $41 Million ARPA-H Initiative to Build the Future of Robotic Mobility and Independence
PITTSBURGH, Nov. 6, 2025 /PRNewswire/ — Assistive Technology Development, Inc. (ATDev) announced today that it is a subcontractor for the Robotic Assistive... Read more.
STAGWELL INC. (NASDAQ: STGW) REPORTS RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025
Q3 YoY Revenue Growth of 4%, Q3 YoY Net Revenue Growth of 6% Q3 YoY Net Revenue Growth excluding Advocacy of 10%, Digital Transformation Net Revenue Growth of 12%,... Read more.
ResumeBuilder.com Survey: 1 in 3 Dating App Users Are Swiping for Jobs, Not Love
Many users are leveraging dating apps for networking, mentorship, and even job offers GUAYNABO, Puerto Rico, Nov. 6, 2025 /PRNewswire/ — ResumeBuilder.com,... Read more.
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO, Nov. 6,... Read more.
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial enrollment completed... Read more.
Tripadvisor, Inc. Earnings Press Release Available on Company’s Investor Relations Site
NEEDHAM, Mass., Nov. 6, 2025 /PRNewswire/ — Tripadvisor, Inc. (NASDAQ: TRIP) issued its third quarter 2025 earnings press release which is available now at... Read more.